Morepen Laboratories is currently trading at Rs. 18.20, down by 3.55 points or 16.32% from its previous closing of Rs. 21.75 on the BSE.The scrip opened at Rs. 19.00 and has touched a high and low of Rs. 19.65 and Rs. 17.55 respectively. So far 471090 shares were traded on the counter.The BSE group `B` stock of face value Rs. 2 has touched a 52 week high of Rs. 27.80 on 01-Nov-2018 and a 52 week low of Rs. 14.70 on 21-Feb-2019.Last one week high and low of the scrip stood at Rs. 24.00 and Rs. 17.05 respectively. The current market cap of the company is Rs. 825.43 crore.The promoters holding in the company stood at 34.54%, while Institutions and Non-Institutions held 14.73% and 50.73% respectively.Securities and Exchange Board of India (SEBI) has directed prohibition on securities market`s access and restraining from buying, selling or otherwise dealing in the securities, either directly or indirectly or in any other manner whatsoever, for a period of one year, to Morepen Laboratories. In this regard, the Company is seeking advice for pursuing suitable remedies including filing of appeal before the appropriate forum.Morepen Laboratories is a well-known pharma company having well equipped Research & Development Centre and is all set to seize the Generic revolution in pharma industry, by filing multiple DMFs and COS for new APIs.

The sales for the March 2019 quarter moved up 30.24% to Rs. 2060.73 millions as compared to Rs. 1582.22 millions during the corresponding quarter last year.The Net Profit of the company reported a remarkable increase of 124.52% to Rs. 92.21  millions  from Rs. 41.07 millions in previous same quarter.The company reported a good operating profit of 210.91 millions compared to 146.71 millions of corresponding previous quarter. (Rs. in Million) Quarter ended Year to Date Year ended 201903 201803 % Var 201903 201803 % Var 201903 201803 % Var Sales 2060.73 1582.22 30.24 7172.43 5608.30 27.89 7172.43 5608.30 27.89 Other Income 10.28 1.20 756.67 36.72 35.40 3.73 36.72 35.40 3.73 PBIDT 210.91 146.71 43.76 686.92 638.10 7.65 686.92 638.10 7.65 Interest 9.19 7.94 15.74 20.71 42.95 -51.78 20.71 42.95 -51.78 PBDT 201.72 138.77 45.36 666.21 595.15 11.94 666.21 595.15 11.94 Depreciation 109.50 97.70 12.08 380.08 334.00 13.80 380.08 334.00 13.80 PBT 92.21 41.07 124.52 286.13 261.15 9.57 286.13 261.15 9.57 TAX 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Deferred Tax 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 PAT 92.21 41.07 124.52 286.13 261.15 9.57 286.13 261.15 9.57 Equity 899.59 899.59 0.00 899.59 899.59 0.00 899.59 899.59 0.00 PBIDTM(%) 10.23 9.27 10.37 9.58 11.38 -15.83 9.58 11.38 -15.83

The sales for the December 2018 quarter moved up 40.07% to Rs. 1983.24 millions as compared to Rs. 1415.94 millions during the corresponding quarter last year.Profit after tax improved marginally to Rs. 97.38  millions for the quarter ended December 2018 from Rs. 96.71 millions of corresponding previous quarter.OP of the company witnessed a marginal growth to 192.00 millions from 181.71 millions in the same quarter last year. (Rs. in Million) Quarter ended Year to Date Year ended 201812 201712 % Var 201812 201712 % Var 201803 201703 % Var Sales 1983.24 1415.94 40.07 5111.70 4026.08 26.96 5608.30 5475.10 2.43 Other Income 24.34 11.42 113.13 26.44 34.20 -22.69 35.40 37.16 -4.74 PBIDT 192.00 181.71 5.66 476.03 491.39 -3.13 638.10 642.03 -0.61 Interest 4.17 8.99 -53.62 11.52 35.01 -67.10 42.95 74.74 -42.53 PBDT 187.83 172.72 8.75 464.50 456.38 1.78 595.15 567.29 4.91 Depreciation 90.45 76.01 19.00 270.58 236.30 14.51 334.00 335.61 -0.48 PBT 97.38 96.71 0.69 193.92 220.08 -11.89 261.15 231.68 12.72 TAX 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Deferred Tax 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 PAT 97.38 96.71 0.69 193.92 220.08 -11.89 261.15 231.68 12.72 Equity 899.59 899.59 0.00 899.59 899.59 0.00 899.59 899.59 0.00 PBIDTM(%) 9.68 12.83 -24.56 9.31 12.21 -23.70 11.38 11.73 -2.97

A fair growth of 22.86% in the revenue at Rs. 1508.36 millions was reported in the June 2018 quarter as compared to Rs. 1227.73 millions during year-ago period.The Company has registered profit of Rs. 23.64  millions for the quarter ended June 2018, a growth of 20.55%  over Rs. 19.61 millions millions achieved in the corresponding quarter of last year.Operating Profit saw a handsome growth to 118.13 millions from 116.68 millions in the quarter ended June 2018. (Rs. in Million) Quarter ended Year to Date Year ended 201806 201706 % Var 201806 201706 % Var 201803 201703 % Var Sales 1508.36 1227.73 22.86 1508.36 1227.73 22.86 5608.30 5475.10 2.43 Other Income 0.76 14.21 -94.65 0.76 14.21 -94.65 35.40 37.16 -4.74 PBIDT 118.13 116.68 1.24 118.13 116.68 1.24 638.10 642.03 -0.61 Interest 4.30 13.07 -67.10 4.30 13.07 -67.10 42.95 74.74 -42.53 PBDT 113.83 103.61 9.86 113.83 103.61 9.86 595.15 567.29 4.91 Depreciation 88.33 84.00 5.15 88.33 84.00 5.15 334.00 335.61 -0.48 PBT 25.50 19.61 30.04 25.50 19.61 30.04 261.15 231.68 12.72 TAX 1.86 0.00 0.00 1.86 0.00 0.00 0.00 0.00 0.00 Deferred Tax 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 PAT 23.64 19.61 20.55 23.64 19.61 20.55 261.15 231.68 12.72 Equity 899.59 899.59 0.00 899.59 899.59 0.00 899.59 899.59 0.00 PBIDTM(%) 7.83 9.50 -17.59 7.83 9.50 -17.59 11.38 11.73 -2.97

Morepen Laboratories is currently trading at Rs. 33.05, up by 1.20 points or 3.77 % from its previous closing of Rs. 31.85 on the BSE.The scrip opened at Rs. 32.45 and has touched a high and low of Rs. 34.05 and Rs. 32.45 respectively. So far 251088 shares were traded on the counter.The BSE group `B` stock of face value Rs. 2 has touched a 52 week high of Rs. 44.35 on 12-Jan-2018 and a 52 week low of Rs. 14.80 on 11-Aug-2017.Last one week high and low of the scrip stood at Rs. 34.05 and Rs. 27.15 respectively. The current market cap of the company is Rs. 1432.70 crore.The promoters holding in the company stood at 34.54%, while Institutions and Non-Institutions held 14.62% and 50.84% respectively.Morepen Laboratories has received USFDA (United States Food and Drug Administration) approvals for both its bulk drugs manufacturing facilities situated in Himachal Pradesh. The Baddi facility has got USFDA approval for the manufacture of bulk drug Atorvastatin Calcium a Cholesterol reducing drug, while the Masulkhana facility has got the nod for manufacturing an anti-asthma bulk drug Montelukast Sodium for export to the US market. The US market size for these two bulk drugs namely Atorvastatin Calcium and Montelukast Sodium is around Rs 5000 crore and Rs 2000 crore respectively. The two APIs collectively contributes around Rs 150 crore annual revenue to the company’s topline and constitutes 44% of the company’s total API business.Morepen is a well-known pharma company having well equipped Research & Development Centre and is all set to seize the Generic revolution in pharma industry, by filing multiple DMFs and COS for new APIs.

The revenue for the March 2018 quarter is pegged at Rs. 1582.22 millions, about 9.22% up against Rs. 1448.71 millions recorded during the year-ago period.The Company to register a -42.58%  fall in the net profit for the quarter ended March 2018.A decline of 146.71 millions was observed in the OP in the quarter ended March 2018 from 166.93 millions on QoQ basis. (Rs. in Million) Quarter ended Year to Date Year ended 201803 201703 % Var 201803 201703 % Var 201803 201703 % Var Sales 1582.22 1448.71 9.22 5608.30 5475.10 2.43 5608.30 5475.10 2.43 Other Income 1.20 27.05 -95.56 35.40 37.16 -4.74 35.40 37.16 -4.74 PBIDT 146.71 166.93 -12.11 638.10 642.03 -0.61 638.10 642.03 -0.61 Interest 7.94 11.49 -30.90 42.95 74.74 -42.53 42.95 74.74 -42.53 PBDT 138.77 155.44 -10.72 595.15 567.29 4.91 595.15 567.29 4.91 Depreciation 97.70 83.92 16.42 334.00 335.61 -0.48 334.00 335.61 -0.48 PBT 41.07 71.52 -42.58 261.15 231.68 12.72 261.15 231.68 12.72 TAX 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Deferred Tax 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 PAT 41.07 71.52 -42.58 261.15 231.68 12.72 261.15 231.68 12.72 Equity 899.59 899.59 0.00 899.59 899.59 0.00 899.59 899.59 0.00 PBIDTM(%) 9.27 11.52 -19.53 11.38 11.73 -2.97 11.38 11.73 -2.97

With no major difference for the quarter endedDecember 2017 , the total revenue stood at Rs. 1415.94  millions.The Net Profit of the company vaulted to 106.65% to Rs. 96.71  millions from Rs. 46.80 millions in the previous quarter.Operating profit for the quarter ended December 2017 rose to 181.71 millions as compared to 153.43 millions of corresponding quarter ended December 2016. (Rs. in Million) Quarter ended Year to Date Year ended 201712 201612 % Var 201712 201612 % Var 201703 201603 % Var Sales 1415.94 1390.33 1.84 4026.08 4026.39 -0.01 5370.35 4524.63 18.69 Other Income 11.42 0.15 7513.33 34.20 9.91 245.11 36.95 11.72 215.27 PBIDT 181.71 153.43 18.43 491.39 474.93 3.47 635.89 653.75 -2.73 Interest 8.99 22.33 -59.74 35.01 63.26 -44.66 69.86 104.13 -32.91 PBDT 172.72 131.10 31.75 456.38 411.67 10.86 566.03 549.62 2.99 Depreciation 76.01 84.30 -9.83 236.30 251.71 -6.12 335.61 349.22 -3.90 PBT 96.71 46.80 106.65 220.08 159.96 37.58 230.42 200.40 14.98 TAX 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -1.37 0.00 Deferred Tax 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 PAT 96.71 46.80 106.65 220.08 159.96 37.58 230.42 201.77 14.20 Equity 899.59 899.59 0.00 899.59 899.59 0.00 899.59 899.59 0.00 PBIDTM(%) 12.83 11.04 16.29 12.21 11.80 3.47 11.84 14.45 -18.05

Morepen Laboratories is currently trading at Rs. 27.80, up by 2.55 points or 10.10% from its previous closing of Rs. 25.25 on the BSE.The scrip opened at Rs. 25.05 and has touched a high and low of Rs. 28.30 and Rs. 25.05 respectively. So far 1007401 shares were traded on the counter.The BSE group `B` stock of face value Rs. 2 has touched a 52 week high of Rs. 28.85 on 05-Dec-2017 and a 52 week low of Rs. 14.80 on 11-Aug-2017.Last one week high and low of the scrip stood at Rs. 28.30 and Rs. 23.60 respectively. The current market cap of the company is Rs. 1203.29 crore.The promoters holding in the company stood at 34.54%, while Institutions and Non-Institutions held 18.80% and 46.66% respectively.Morepen Laboratories has received approval from United States Food and Drug Administration (USFDA) for Montelukast Sodium, a bulk drug / API to sell in the US market. This gives Morepen an entry into the Rs 2000 crore US market for Montelukast. The first commercial orders for the bulk drug are expected in Q2 of FY 2018-19.Morepen is a well-known pharma company having well equipped Research & Development Centre and is all set to seize the Generic revolution in pharma industry, by filing multiple DMFs and COS for new APIs.

Morepen Laboratories is currently trading at Rs. 18.25, up by 0.45 points or 2.53% from its previous closing of Rs. 17.80 on the BSE.The scrip opened at Rs. 18.60 and has touched a high and low of Rs. 18.70 and Rs. 18.20 respectively. So far 109698 shares were traded on the counter.The BSE group `B` stock of face value Rs. 2 has touched a 52 week high of Rs. 25.10 on 09-Nov-2016 and a 52 week low of Rs. 14.80 on 11-Aug-2017.Last one week high and low of the scrip stood at Rs. 18.95 and Rs. 16.85 respectively. The current market cap of the company is Rs. 820.93 crore.The promoters holding in the company stood at 34.54%, while institutions and non-institutions held 18.80% and 46.66% respectively.In a bid to aggressively tap the growing probiotics market in India, Morepen Laboratories has reportedly entered into partnership with Belgium`s Vesale Pharma. The move is expected to contribute Rs 100 crore to the Indian company`s topline in five years. Moreover, the company will soon be launching four major probiotics developed by Vesale Pharma in the Indian market.Morepen is a well-known pharma company having well equipped Research & Development Centre and is all set to seize the Generic revolution in pharma industry, by filing multiple DMFs and COS for new APIs.

The Sales for the quarter ended March 2017 of Rs. 0.00 million declined by -100.00% from Rs. 1235.93 millions.The Company has posted about -100.00%  dip in net profit at Rs. 0.00  millions in the quarter ended March 2017,against Rs . 71.69 millions  million in the same period of last fiscal year.The Operating Profit of the company witnessed a decrease to 0.00 millions from 186.25 millions. (Rs. in Million) Quarter ended Year to Date Year ended 201703 201603 % Var 201703 201603 % Var 201703 201603 % Var Sales 0.00 1235.93 -100.00 0.00 4524.63 -100.00 0.00 4524.63 -100.00 Other Income 0.00 6.78 0.00 0.00 11.72 0.00 0.00 11.72 0.00 PBIDT 0.00 186.25 -100.00 0.00 653.76 -100.00 0.00 653.76 -100.00 Interest 0.00 26.84 -100.00 0.00 104.13 -100.00 0.00 104.13 -100.00 PBDT 0.00 159.41 -100.00 0.00 549.63 -100.00 0.00 549.63 -100.00 Depreciation 0.00 87.72 0.00 0.00 349.22 0.00 0.00 349.22 0.00 PBT 0.00 71.69 0.00 0.00 200.41 0.00 0.00 200.41 0.00 TAX 0.00 0.00 0.00 0.00 -1.37 0.00 0.00 -1.37 0.00 Deferred Tax 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 PAT 0.00 71.69 -100.00 0.00 201.78 -100.00 0.00 201.78 -100.00 Equity 0.00 899.59 0.00 0.00 899.59 0.00 0.00 899.59 0.00 PBIDTM(%) 0.00 15.07 0.00 0.00 14.45 0.00 0.00 14.45 0.00

Morepen Laboratories has informed about Standalone Financial Results & Limited Review for the period ended December 31, 2016.The above information is a part of company’s filings submitted to BSE.

The Exchange has sought clarification from the company on September 23, 2016, with reference to news flashed on Economic Times dated September 23, 2016 stating ‘Morepen in Talks to Sell OTC Business to Piramals’.The above information is a part of company’s filings submitted to BSE.